Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Putting the Patient in Labeling (And Drug Approval Decisions) in ODE 1

This article was originally published in RPM Report

Executive Summary

The Office of Drug Evaluation 1 (Cardio-Renal, Neurology, and Psychiatry) remains a bastion of FDA traditionalism. The long-time spiritual/intellectual leader of the group, Bob Temple, has been cautious about how to accept patient input into FDA approval criteria for drugs reviewed in these areas. Recent remarks by the ODE 1 division director, however, suggest that the patient’s perspective is very much now on the minds of this group.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts